HBB rs121912652: Hemoglobin C and Malaria Protection
The rs121912652 variant is a well-studied single nucleotide change located in the HBB gene on chromosome 11, responsible for encoding the beta-globin subunit of adult hemoglobin. The minor allele converts normal hemoglobin into Hemoglobin C (HbC), historically designated as p.Glu6Lys (or p.Glu7Lys under modern HGVS nomenclature). Carrying this variant is strongly associated with protection against severe Plasmodium falciparum malaria, while homozygous or compound heterozygous genotypes can cause mild hemolytic anemia or complex hemoglobinopathies.
What each genotype means
Typical beta-globin profile
You carry two reference copies of the HBB gene encoding normal adult hemoglobin A. Research shows this genotype is associated with standard red blood cell morphology and typical susceptibility to Plasmodium falciparum malaria.
Found in more than 99% of individuals across global populations, but present at lower frequencies (around 70% to 85%) in parts of West Africa.
Hemoglobin C trait carrier
You carry one copy of the hemoglobin C allele alongside one reference copy, representing the HbAC carrier state. Carriers are typically asymptomatic without significant hematologic disease and have demonstrated substantial protection against severe malaria in population studies.
Carried by up to 10% to 15% of individuals of West African ancestry, while remaining exceedingly rare (well below 0.1%) in European, Asian, and other populations.
Hemoglobin C disease
You carry two copies of the hemoglobin C allele, historically designated as homozygous HbCC. In clinical literature, this genotype is associated with hemoglobin C disease, typically characterized by mild hemolytic anemia and enlarged spleen, along with strong protection against severe malaria.
Found in approximately 1% to 2% of people in specific regions of West Africa, such as Burkina Faso and Mali, and occurs extremely rarely elsewhere.
Genetic Architecture and Molecular Impact
The single nucleotide polymorphism rs121912652 is located within the human hemoglobin subunit beta (HBB) gene on chromosome 11. Specifically, the variant represents a c.19G>A point mutation in the coding sequence. This nucleotide substitution alters codon 6 of the mature beta-globin protein (or codon 7 when counting the initial methionine residue) from a negatively charged glutamic acid to a positively charged lysine (p.Glu7Lys, historically known as p.Glu6Lys). Beta-globin is an indispensable polypeptide that combines with alpha-globin subunits and iron-bearing heme groups to assemble adult hemoglobin (HbA), the primary oxygen carrier in human erythrocytes. When the lysine substitution is introduced, the resulting hemoglobin molecule is designated as Hemoglobin C (HbC). The altered charge changes the electrostatic properties and physical behavior of the protein, significantly decreasing hemoglobin solubility and promoting cellular dehydration and intra-erythrocytic crystal formation under physiological conditions.
Evolutionary Significance and Malaria Protection
Decades of population genetics and epidemiological research have demonstrated that the rs121912652 variant has undergone positive natural selection due to the evolutionary pressure of endemic malaria. Similar to the sickle hemoglobin variant (HbS), carrying the HbC allele provides substantial protection against severe, life-threatening complications caused by the mosquito-borne parasite Plasmodium falciparum. In vitro and clinical observational studies indicate that erythrocytes containing Hemoglobin C impair parasite growth, slow intracellular replication, and alter the presentation of parasite-derived surface proteins, thereby reducing microvascular sequestration. Heterozygous individuals (genotype GA, carrying the Hemoglobin C trait) experience moderate protection against clinical malaria without notable pathology. Homozygous individuals (genotype AA) gain near-complete protection from complicated malaria. Unlike the severe lethality associated with untreated homozygous sickle cell disease (HbSS), homozygous HbC typically produces only mild clinical manifestations, allowing the allele to reach elevated frequencies in specific endemic regions.
Clinical Characteristics and Compound Heterozygosity
The clinical consequences of rs121912652 depend largely on zygosity and co-inherited globin alleles. Individuals who are heterozygous (GA) are classified as having Hemoglobin C trait; they are generally asymptomatic and exhibit normal life expectancy, although a routine complete blood count may show mild microcytosis or target cells. Homozygous individuals (AA), diagnosed with Hemoglobin C disease, typically experience mild chronic hemolytic anemia, splenomegaly, and red blood cell rigidity due to crystal formation, but generally enjoy normal growth and development. However, significant clinical complexity arises in compound heterozygotes who inherit rs121912652 alongside other pathogenic HBB mutations. Most notably, co-inheritance of the HbC allele with the sickle cell allele (HbS) leads to Hemoglobin SC disease, a chronic sickling disorder characterized by hemolytic anemia, vaso-occlusive episodes, and retinopathy. Similarly, co-inheritance with beta-thalassemia mutations produces Hemoglobin C-beta thalassemia, a moderate-to-severe microcytic anemia requiring specialized medical follow-up.
Navigating Genetic Results Responsibly
Genetic data identifying rs121912652 should be viewed as educational and screening information rather than a standalone clinical diagnosis. Direct-to-consumer genotyping platforms may detect the variant, but confirmatory testing—such as high-performance liquid chromatography (HPLC), hemoglobin electrophoresis, or targeted clinical sequencing—is standard for clinical verification. Understanding one's carrier status is particularly relevant for family planning and reproductive counseling, especially for couples where one or both partners carry variants for sickle cell, beta-thalassemia, or Hemoglobin C. Because the clinical presentation of compound states can vary widely, individuals with questions about their carrier status, prospective risks for offspring, or hematologic parameters should consult a hematologist, certified genetic counselor, or primary healthcare provider rather than making independent medical choices.
How common is this variant?
The variant is common across West Africa, reaching allele frequencies of 10% to 15% in Burkina Faso, Ghana, and Togo, while remaining very rare (<0.1%) in non-African ancestral populations.
Frequently asked questions
Does having the Hemoglobin C trait cause health problems?
Individuals who carry one copy of the Hemoglobin C variant (heterozygous GA) are typically asymptomatic and experience normal health and life expectancy. Routine blood tests might reveal slightly smaller red blood cells (mild microcytosis) or target cells on a blood smear, but these findings rarely require medical intervention.
What is the difference between Hemoglobin C and Hemoglobin S?
Both variants occur at the same location within the beta-globin protein (codon 6/7 of the HBB gene), but they involve different amino acid substitutions. Hemoglobin S substitutes valine and causes sickle cell anemia, which can lead to severe vaso-occlusive crises, whereas Hemoglobin C substitutes lysine and generally causes much milder hemolytic symptoms.
Why is the Hemoglobin C allele so common in West Africa?
The variant rose in frequency due to natural selection against severe Plasmodium falciparum malaria. Because individuals carrying the allele have a strong survival advantage in malaria-endemic zones and homozygous individuals avoid the severe mortality associated with sickle cell anemia, the allele expanded rapidly throughout West Africa.
Can Hemoglobin C be inherited alongside sickle cell disease?
Yes. If an individual inherits the Hemoglobin C allele from one parent and the sickle cell allele (HbS) from the other, they develop Hemoglobin SC disease. This condition is a chronic sickling disorder that presents with intermittent pain crises, anemia, and other complications, usually slightly milder than classic homozygous sickle cell anemia (HbSS).
Sources & further reading
Educational information only, last refreshed 9/10/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121912652?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in HBB
This variant is a pathogenic mutation in the HBB gene associated with beta-thalassemia.
This variant is a pathogenic mutation in the HBB gene associated with hemoglobinopathies such as sickle cell disease.
This variant (c.20A>T, p.Glu7Val) causes the substitution of valine for glutamic acid in the beta-globin chain, leading to sickle cell trait or disease depending on zygosity.
Pathogenic variant (p.Glu6Val, HbS-Antilles) in HBB associated with sickle cell disease-like pathology.
Pathogenic nonsense mutation (c.118C>T / p.Gln40Ter / codon 39 nonsense) causing beta-zero thalassemia and classic carrier status (beta-thalassemia minor).
This variant, known as Hb C-Harlem, involves a double mutation in the HBB gene that can lead to sickle-beta-thalassemia-like phenotypes.